Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice

Molecular Metabolism

Volumn 5, Issue 8, 2016, Pages 725-730

  Arora, Tulika ^a   Wegmann, Udo ^b   Bobhate, Anup ^b   Lee, Ying Shiuan ^a   Greiner, Thomas U ^a   Drucker, Daniel J ^c   Narbad, Arjan ^b   Bäckhed, Fredrik ^a,d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b INSTITUTE OF FOOD RESEARCH   (United Kingdom)

^c MOUNT SINAI HOSPITAL   (Canada)

^d Capital Region   (Denmark)

Author keywords

GLP 1; Glucose tolerance; Lactococcus lactis; Recombinant bacteria

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE 6 PHOSPHATASE; INSULIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP);

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; GENE EXPRESSION; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; INSULIN RELEASE; INSULIN TOLERANCE TEST; LACTOCOCCUS LACTIS; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 84989967664     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2016.06.006     Document Type: Article

References (19)

1. [1] Drucker, D.J., The role of gut hormones in glucose homeostasis. The Journal of Clinical Investigation 117 (2007), 24–32.
2. [2] Tomkin, G.H., Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors. World Journal of Diabetes 5 (2014), 636–650.
3. [3] Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., Ceriello, A., Comparison review of short-acting and long-acting glucagon-like peptide-1 receptor agonists. Diabetes Therapy 6 (2015), 239–256.
4. [4] Akiyode, O.F., desoye, A.A.A., Adverse effects associated with newer diabetes therapies: a review article Journal of Pharmacy Practice [Epub ahead of print].
5. [5] Kunji, E.R., Slotboom, D.J., Poolman, B., Lactococcus lactis as host for overproduction of functional membrane proteins. Biochimica et Biophysica Acta 1610 (2003), 97–108.
6. [6] Steidler, L., Hans, W., Schotte, L., Neirynck, S., Obermeier, F., Falk, W., et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289 (2000), 1352–1355.
7. [7] Braat, H., Rottiers, P., Hommes, D.W., Huyghebaert, N., Remaut, E., Remon, J.P., et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clinical Gastroenterology and Hepatology 4 (2006), 754–759.
8. [8] Wegmann, U., Klein, J.R., Drumm, I., Kuipers, O.P., Henrich, B., Introduction of peptidase genes from Lactobacillus delbrueckii subsp. lactis into Lactococcus lactis and controlled expression. Applied and Environmental Microbiology 65 (1999), 4729–4733.
9. [9] Dodd, H.M., Horn, N., Hao, Z., Gasson, M., A lactococcal expression system for engineered nisins. Applied and Environmental Microbiology 58 (1992), 3683–3693.
10. [10] Wichmann, A., Allahyar, A., Greiner, T.U., Plovier, H., Lunden, G.O., Larsson, T., et al. Microbial modulation of energy availability in the colon regulates intestinal transit. Cell Host & Microbe 14 (2013), 582–590.
11. [11] Agarwal, P., Khatri, P., Billack, B., Low, W.K., Shao, J., Oral delivery of glucagon like peptide-1 by a recombinant Lactococcus lactis. Pharmaceutical Research 31 (2014), 3404–3414.
12. [12] Fernandez, A., Horn, N., Wegmann, U., Nicoletti, C., Gasson, M.J., Narbad, A., Enhanced secretion of biologically active murine interleukin-12 by Lactococcus lactis. Applied and Environmental Microbiology 75 (2009), 869–871.
13. [13] Drucker, D.J., The biology of incretin hormones. Cell Metabolism 3 (2006), 153–165.
14. [14] Burcelin, R., Da Costa, A., Drucker, D., Thorens, B., Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 50 (2001), 1720–1728.
15. [15] Cantini, G., Mannucci, E., Luconi, M., Perspectives in GLP-1 research: new targets, new receptors. Trends in Endocrinology & Metabolism 27 (2016), 427–438.
16. [16] Lee, Y.-S., Shin, S., Shigihara, T., Hahm, E., Liu, M.-J., Han, J., et al. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes 56 (2007), 1671–1679.
17. [17] Winzell, M.S., Ahrén, B., The high-fat diet-fed mouse. A model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53 (2004), S215–S219.
18. [18] Zander, M., Madsbad, S., Madsen, J.L., Holst, J.J., Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. The Lancet 359 (2002), 824–830.
19. [19] Kappe, C., Zhang, Q., Nyström, T., Sjöholm, Å., Effects of high-fat diet and the anti-diabetic drug metformin on circulating GLP-1 and the relative number of intestinal L-cells. Diabetology & Metabolic Syndrome 6 (2014), 1–8.